EFC16034: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis (GEMINI 2)

Grants and Contracts Details

StatusFinished
Effective start/end date8/20/201/12/24

Funding

  • Sanofi Aventis US Inc: $13,631.00